指南与共识慢性肾脏病肾小球疾病

慢性肾脏病:2019 EULAR/ERA-EDTA 狼疮肾炎推荐中缺失的概念

Chronic kidney disease: the missing concept in the 2019 EULAR/ERA-EDTA recommendations for lupus nephritis.
指南 / 共识 · Nephrol Dial Transplant · 2023-01-01

文章指出慢性肾脏病(CKD)诊断阈值为 GFR<60 ml/min/1.73 m² 或 UACR≥30 mg/g,并按 GFR 与 UACR 分轻、中、重度,中重度对应高或极高心血管风险。狼疮肾炎(LN)是 CKD 的病因,但 2019 EULAR/ERA-EDTA 狼疮肾炎管理推荐和 2022 EULAR 风湿病心血管风险管理推荐均未讨论白蛋白尿或 CKD。作者建议将 LN 视为 CKD 的病因,在未另有证明时沿用大型 CKD 试验证据。

要点

  • CKD 诊断阈值为 GFR<60 ml/min/1.73 m² 或 UACR≥30 mg/g。
  • CKD 按 GFR 与 UACR 分轻、中、重度,中重度分别对应高或极高心血管风险。
  • 2019 EULAR/ERA-EDTA 狼疮肾炎推荐与 2022 EULAR 心血管风险管理推荐未讨论白蛋白尿或 CKD。

核心结论

  • 作者提出应将 LN 从独立于 CKD 的概念框架,转变为 LN 是 CKD 病因的框架,未另有证明时大型 CKD 试验证据适用。

研究设计与样本

  • 本文为对 2019 EULAR/ERA-EDTA 狼疮肾炎推荐及 2022 EULAR 风湿病心血管风险管理推荐的评述性文章。

主要发现

  • 2019 EULAR/ERA-EDTA 狼疮肾炎推荐未讨论白蛋白尿或 CKD。
  • 2022 EULAR 风湿病与肌肉骨骼疾病心血管风险管理推荐亦未讨论白蛋白尿或 CKD。
  • 推荐中讨论的蛋白尿目标值可能出现在严重 CKD 且心血管风险极高的患者中,这些患者或可从 2021 ESC 心血管疾病预防指南的指导中获益。

关键数值与推荐

  • CKD 诊断:GFR 低于 60 ml/min/1.73 m² 或 UACR 达到 ≥30 mg/g。
  • CKD 分轻、中、重度,中度对应高心血管风险,重度对应极高心血管风险。
  • CKD 也可基于组织学或影像学发现的异常来诊断。

临床怎么用

  • 原文未据此给出具体临床推荐;作者建议将 LN 视为 CKD 的病因,并沿用大型 CKD 试验证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) is diagnosed when glomerular filtration rate (GFR) falls below 60 ml/min/1.73 m2 or urinary albumin:creatinine ratio (UACR) reaches ≥30 mg/g, as these two thresholds indicate a higher risk of adverse health outcomes, including cardiovascular mortality. CKD is classified as mild, moderate or severe, based on GFR and UACR values, and the latter two classifications convey a high or very high cardiovascular risk, respectively. Additionally, CKD can be diagnosed based on abnormalities detected by histology or imaging. Lupus nephritis (LN) is a cause of CKD. Despite the high cardiovascular mortality of patients with LN, neither albuminuria nor CKD are discussed in the 2019 European League Against Rheumatism (EULAR)/European Renal Association-European Dialysis and Transplant Association recommendations for the management of LN or the more recent 2022 EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases. Indeed, the proteinuria target values discussed in the recommendations may be present in patients with severe CKD and a very high cardiovascular risk who may benefit from guidance detailed in the 2021 European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice. We propose that the recommendations should move from a conceptual framework of LN as an entity separate from CKD to a framework in which LN is considered a cause of CKD and evidence generated from large CKD trials applies unless demonstrated otherwise.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Rojas-Rivera JE, Bakkaloglu SA, Bolignano D, et al. Chronic kidney disease: the missing concept in the 2019 EULAR/ERA-EDTA recommendations for lupus nephritis. Nephrol Dial Transplant. 2023. PMID: 37433583. doi:10.1093/ndt/gfad154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。